A PHASE I/II, OPEN LABEL STUDY OF SPC2996 IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED FOLLICULAR OR LYMPHOPLASMACYTIC NON-HODGKIN’S LYMPHOMA Primary: 1. To determine the MTD of SPC2996 in combination with rituximab in patients with relapsed follicular or lymphoplasmacytic non-Hodgkin’s lymphoma 2. To determine the overall response rate (Co...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Santaris SPC2996-101 : Essai de phase 1, 2 en escalade de dose évaluant l’efficacité et la tolérance d’un traitement par SPC2996 chez des patients ayant une leucémie lymphocytaire chronique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] An open-labelled, international, multicenter, dose escalating, phase I/II study of SPC2996, an LNA antisense molecule against BCL-2, in patients with relapsed or refractory chronic lymphocytic leukaem...

• Pays France
• Organes Leucémies chroniques
• Spécialités Chimiothérapie

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Antiviral Activity of SPC3649 (miravirsen) Administered to Treatment-Naïve Subjects with Chronic Hepatitis C (CHC) Infection The primary objective of this study is to determine the safety and tolerability of multiple doses of miravirsen in HCV genotype 1 infected subjects

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

SPC2996 in Chronic Lymphocytic Leukaemia An open-labelled, international multicenter dose escalating, phase I/II study of SPC2996, an LNA antisense molecule against Bcl-2, in patients with relapsed or refractory Chronic Lymphocytic Leukaemia To investigate the safety and efficacy of SPC2996 in CLL patients

• Pays Aucun
• Organes Aucun
• Spécialités Aucune